206 related articles for article (PubMed ID: 33142288)
21. Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review.
Odaka T; Tominaga K
Curr Ther Res Clin Exp; 2020; 93():100616. PubMed ID: 33320111
[TBL] [Abstract][Full Text] [Related]
22. Specific inhibition of bile acid transport alters plasma lipids and GLP-1.
Rudling M; Camilleri M; Graffner H; Holst JJ; Rikner L
BMC Cardiovasc Disord; 2015 Jul; 15():75. PubMed ID: 26197999
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis.
Luthra P; Camilleri M; Burr NE; Quigley EMM; Black CJ; Ford AC
Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):831-844. PubMed ID: 31474542
[TBL] [Abstract][Full Text] [Related]
24. A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients.
Christie J; Shroff S; Shahnavaz N; Carter LA; Harrison MS; Dietz-Lindo KA; Hanfelt J; Srinivasan S
Am J Gastroenterol; 2017 Feb; 112(2):356-364. PubMed ID: 27922028
[TBL] [Abstract][Full Text] [Related]
25. Elobixibat for the treatment of constipation.
Wong BS; Camilleri M
Expert Opin Investig Drugs; 2013 Feb; 22(2):277-84. PubMed ID: 23215781
[TBL] [Abstract][Full Text] [Related]
26. Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events.
Ohbayashi H; Sato Y; Kiuchi M; Asano T; Nagazumi A; Kimura T
Expert Rev Gastroenterol Hepatol; 2021 Mar; 15(3):333-342. PubMed ID: 33206011
[TBL] [Abstract][Full Text] [Related]
27. Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial.
Marciniak CM; Toledo S; Lee J; Jesselson M; Bateman J; Grover B; Tierny J
World J Gastroenterol; 2014 Nov; 20(43):16323-33. PubMed ID: 25473191
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the impact on efficacy of lubiprostone dose reduction to manage adverse events in the treatment of chronic constipation in Japan.
Ohbayashi H; Sato Y; Kiuchi M; Nagazumi A; Kanzo T; Kimura T
Expert Rev Gastroenterol Hepatol; 2022 Aug; 16(8):809-817. PubMed ID: 35993999
[TBL] [Abstract][Full Text] [Related]
29. Interventions for preventing postpartum constipation.
Turawa EB; Musekiwa A; Rohwer AC
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD011625. PubMed ID: 26387487
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients: A multicenter, randomized, double-blind, placebo-controlled trial.
Xiao YL; Dai N; He SX; Tian A; Liu S; Tian ZB; Wang XY; Li YQ; Hou XH; Fang XC; Wen ZL; Zeng WZ; Xu H; Sun MJ; Liu YL; Wu YD; Shen XZ; Liu XW; Liu L; Chen MH
J Dig Dis; 2021 Nov; 22(11):622-629. PubMed ID: 34633753
[TBL] [Abstract][Full Text] [Related]
31. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
32. Cochrane Review: Osmotic and stimulant laxatives for the management of childhood constipation (Review).
Gordon M; Naidoo K; Akobeng AK; Thomas AG
Evid Based Child Health; 2013 Jan; 8(1):57-109. PubMed ID: 23878124
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of lubiprostone for functional constipation treatment in adolescents and children: Randomized controlled trial.
Elkaragy ES; Shamseya MM; Metwally RH; Mansour ER; Lashen SA
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):800-809. PubMed ID: 38314885
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and safety of lubiprostone after switching from stimulant laxatives in elderly patients with chronic constipation.
Maruyama M; Miida S; Sato T; Kimura T; Watanabe A; Watanabe H; Nishizawa M; Horikawa K; Kajiwara T; Karasawa Y; Hasebe Y; Nozawa K; Terai S
JGH Open; 2023 Sep; 7(9):610-617. PubMed ID: 37744709
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study.
Abe T; Kunimoto M; Hachiro Y; Ohara K; Inagaki M; Murakami M
J Anus Rectum Colon; 2020; 4(3):122-127. PubMed ID: 32743114
[TBL] [Abstract][Full Text] [Related]
36. Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.
Sarosiek I; Bashashati M; Alvarez A; Hall M; Shankar N; Gomez Y; McCallum RW; Sarosiek J
Am J Med Sci; 2016 Sep; 352(3):231-8. PubMed ID: 27650225
[TBL] [Abstract][Full Text] [Related]
37. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
38. Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation.
Nakajima A; Ishizaki S; Matsuda K; Kurosu S; Taniguchi S; Gillberg PG; Mattsson JP; Hasunuma T; Camilleri M
J Gastroenterol Hepatol; 2022 May; 37(5):883-890. PubMed ID: 35168298
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacological characteristics and clinical study results of ileal bile acid transporter inhibitor elobixibat (GOOFICE
Ikeda N; Taniguchi S; Seki M
Nihon Yakurigaku Zasshi; 2019; 153(3):129-138. PubMed ID: 30867382
[TBL] [Abstract][Full Text] [Related]
40. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Johanson JF; Morton D; Geenen J; Ueno R
Am J Gastroenterol; 2008 Jan; 103(1):170-7. PubMed ID: 17916109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
